Clinical Trials on Alzheimer's Disease (CTAD) 2024- 17th

CONFERENCE COVERAGE SERIES Trontinemab Data Strengthen Hope for Brain Shuttles Donanemab: Small Tweak in Titration, Big Gain in Safety? Clinical Trials on Alzheimer's Disease (CTAD) 2024- 17th

Joshua Grill, Frank LaFerla on Remembering Bruce Albala, 70, Leader in BACE Inhibitor Development

COMMENT The UC Irvine ADRC was shocked and saddened by the passing of Dr. Bruce Albala. Dr. Albala brought his unique insights to UC Irvine in 2019 and was a frequent attendee at seminars and other activities held by the ADRC, while devoting most of his energy to

Paul Maruff on Remembering Bruce Albala, 70, Leader in BACE Inhibitor Development

COMMENT I miss Bruce Albala. Bruce’s scientific life was dedicated to the development of a drug treatment for Alzheimer's disease. He had begun in the industry before me and would tell me tales of his life before donepezil. He had worked in companies whose n

Pierre Vandepapeliere

Amyl Tx
Belgium

Poppy Fu

London, United Kingdom

Suleyman Can Akerman

Johns Hopkins
Baltimore, United States

Eda Karakaya

Medical University of South Carolina
United States

TcMAC21

RESEARCH MODELS TcMAC21 is a Down syndrome mouse model which contains a nearly complete and freely segregating human chromosome 21 (including the APP gene) in the form of a hybrid mouse artificial chromosome, with no detectable mosaicism in a broad spectrum of tissues an

PAPER Shao LR, Gao F, Chinnasamy V, Kazuki Y, Oshimura M, Reeves RH, Stafstrom CE

Increased propensity for infantile spasms and altered neocortical excitation-inhibition balance in a mouse model of down syndrome carrying human chromosome 21.

Neurobiol Dis. 2023 Aug;184:106198. Epub 2023 Jun 13 PubMed.

PAPER Sarver DC, Xu C, Rodriguez S, Aja S, Jaffe AE, Gao FJ, Delannoy M, Periasamy M, Kazuki Y, Oshimura M, Reeves RH, Wong GW

Hypermetabolism in mice carrying a near-complete human chromosome 21.

Elife. 2023 May 30;12 PubMed.

PAPER Kazuki Y, Gao FJ, Li Y, Moyer AJ, Devenney B, Hiramatsu K, Miyagawa-Tomita S, Abe S, Kazuki K, Kajitani N, Uno N, Takehara S, Takiguchi M, Yamakawa M, Hasegawa A, Shimizu R, Matsukura S, Noda N, Ogonuki N, Inoue K, Matoba S, Ogura A, Florea LD, Savonenko A, Xiao M, Wu D, Batista DA, Yang J, Qiu Z, Singh N, Richtsmeier JT, Takeuchi T, Oshimura M, Reeves RH

A non-mosaic transchromosomic mouse model of down syndrome carrying the long arm of human chromosome 21.

Elife. 2020 Jun 29;9 PubMed.

Sjors Scheres, Michel Goedert on That Mystery “Density” in α-Syn Fibrils: Polyphosphate, Anyone?

COMMENT Cryo-EM reconstructions of amyloid filaments made of the proteins tau, TDP-43, or α-synuclein that were extracted from human brains revealed the presence of additional densities, not attributable to these proteins themselves, whose identity remains unknow

Alzheimer’s & Parkinson’s Drug Development Summit- 13th

CONFERENCE 2025-03-18 00:00:00-2025-03-20 00:00:00 Boston, Massachusetts 18 &#x2013 20 March 2025 View Conference Website 0

PAPER Zachara NE, Akimoto Y, Boyce M, Hart GW

The O-GlcNAc Modification

In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology [Internet]. 4th edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022. . Essentials of Glycobiology [Internet]. 4th edition.

PAPER Vijverberg, E., de Haan, W., Scheijbeler, E. et al

A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer’s Disease

J Prev Alzheimers Dis, 7 Aug 2024 . The Journal of Prevention of Alzhieimer's Disease